Sullivan Timothy Eugene

Average Profitability
1.94%
Insider Buys Quantity
1
Insider Buys Sum
$695,259.87
Insider Sells Quantity
10
Insider Sells Sum
$12.09M

Insider Activity of Sullivan Timothy Eugene

According to the SEC Form 4 filings, Sullivan Timothy Eugene, being in a position of

  1. Chief Financial Officer at Apellis Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 32281 share for $1.92M,
    over all time since 2019-08-29, has bought 23398 shares for $695,260, and sold 146409 shares for $12.09M.

The largest purchase of all time was on 2019-08-29 and amounted to 23398 shares of Apellis Pharmaceuticals, Inc. for $695,260.

The largest sale of all time was on 2023-06-05 and amounted to 37570 shares of Apellis Pharmaceuticals, Inc. for $3.36M.

Biography of Sullivan Timothy Eugene

No biography is available at this moment.

2024-04-01SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
4,000
0.0033%
$58.66$234,640-33.38%
2024-03-01SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
6,000
0.0049%
$63.22$379,340-36.76%
2024-02-12SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
1,431
0.0012%
$67.77$96,974-39.32%
2024-01-29SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
906
0.0008%
$64.14$58,109-36.47%
2024-01-22SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
3,551
0.003%
$65.00$230,801-35.79%
2024-01-16SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
2,235
0.0019%
$66.81$149,317-36.92%
2023-11-30SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
14,158
0.0122%
$54.73$774,884-11.32%
2023-07-03SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
6,779
0.006%
$89.97$609,928-46.1%
2023-06-05SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
37,570
0.0329%
$89.55$3.36M-44.47%
2023-06-05SaleApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
69,779
0.0606%
$88.80$6.2M-44.47%
2019-08-29PurchaseApellis Pharmaceuticals, Inc.
APLS
Chief Financial Officer
23,398
0.0367%
$29.71$695,260+1.94%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.